Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Senator Katie Britt, R-Alabama, took to social media this weekend to criticize the use of artificial food dyes. In a Saturday post on X, Britt shared an April story from WHNT News 19 about a ...

PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its ...

The elimination of 3,500 full-time employees at the FDA risks undermining the very innovation and domestic capacity the ...

A House Energy & Commerce’s Health subcommittee came to a brief halt on Tuesday as the Republican chair asked Health Secretary Robert F. Kennedy Jr. to retract his accusations that a ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

FDA approves new twice-yearly HIV shot. What to know. ... "We now have a very real opportunity to end the HIV epidemic," said Daniel O'Day, chairman and CEO of Gilead Sciences.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...